AKT1 and lung carcinoma: Cisplatin (CDDP), an anti-cancer drug most effective against tumor cells in the resting period, and β- elemene, which inhibits the PI3K/AKT/mTOR axis, were co-treated to lung cancer cell lines such as A549 and NCI-H1650 [189].